Tim Delahaye

Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents

Carsten Riether, Thomas Pabst, Sabine Höpner et al. · Nature Medicine · 2020 · 211 citations

Medicine, Hematology, Oncology +14

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

Nicolas Leupin, Pier Luigi Zinzani, Franck Morschhauser et al. · Cancer · 2021 · 35 citations

Medicine, Oncology, Pharmacology +17

Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models

Jonatan Dewulf, Tal Flieswasser, Tim Delahaye et al. · EJNMMI Radiopharmacy and Chemistry · 2023 · 25 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Argx-110 Targeting CD70, in Combination with Azacitidine, Shows Favorable Safety Profile and Promising Anti-Leukemia Activity in Newly Diagnosed AML Patients in an Ongoing Phase 1/2 Clinical Trial

Adrian F. Ochsenbein, Carsten Riether, Ulrike Bacher et al. · Blood · 2018 · 21 citations

Medicine, Oncology, Pharmacology +15

An open‐label, nonrandomized, phase Ib feasibility study of cusatuzumab in patients with nasopharyngeal carcinoma

Astrid De Meulenaere, Tijl Vermassen, David Creytens et al. · Clinical and Translational Science · 2021 · 19 citations · Full text

Pharmacy, Oncology, Pharmacology +17